VYNE Therapeutics Announces Positive Data from Phase 1a Trial of VYN202

Bridgewater, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) —

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive data from the single ascending dose (“SAD”) portion of its ongoing Phase 1a trial of VYN202. The Phase 1a trial is a two-part, double-blind, placebo-controlled dose-escalation study in healthy volunteers consisting of SAD and multiple ascending dose (“MAD”) components to evaluate the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics of VYN202. Findings from the SAD portion of the Phase 1a trial to date are as follows:

Positive Data from Phase 1a Trial of VYN202

The positive data from the SAD portion of the Phase 1a trial of VYN202 are promising. The study has shown that VYN202 is well-tolerated in healthy volunteers and has demonstrated favorable pharmacokinetic properties. This is an important milestone for VYNE Therapeutics as it signals the potential for VYN202 to be an effective treatment for chronic inflammatory and immune-mediated conditions with high unmet need.

These findings are a significant step forward in the development of VYN202 and provide a strong foundation for further research and clinical trials. The Company plans to continue evaluating the safety and efficacy of VYN202 in the MAD portion of the Phase 1a trial and looks forward to sharing the results with the medical community.

How This Will Affect Me

As a potential future patient with chronic inflammatory or immune-mediated conditions, the positive data from the Phase 1a trial of VYN202 is promising news. If VYN202 proves to be safe and effective in further clinical trials, it could offer a new treatment option for individuals like you who are living with these challenging conditions. This could potentially improve your quality of life and provide relief from symptoms that may be difficult to manage with current treatment options.

How This Will Affect the World

The development of VYN202 has the potential to have a significant impact on the world of healthcare. If VYNE Therapeutics is successful in bringing VYN202 to market, it could help address the unmet needs of patients with chronic inflammatory and immune-mediated conditions around the globe. This could lead to improved outcomes for individuals struggling with these conditions, as well as contribute to the advancement of treatment options in the field of biopharmaceuticals.

Conclusion

In conclusion, the positive data from the Phase 1a trial of VYN202 is an exciting development in the field of biopharmaceuticals. VYNE Therapeutics is making progress in the development of a potential new treatment option for chronic inflammatory and immune-mediated conditions, with the goal of addressing high unmet needs in patient care. As the Company continues with further research and clinical trials, the future looks bright for the potential impact of VYN202 on both individuals and the global healthcare community.